Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers
April 04 2023 - 10:45AM
Business Wire
Webinar to be held Wednesday, April 19, 2023 at 12:00 pm ET /
6:00 pm CET
Regulatory News:
TRANSGENE (Paris:TNG), a biotech company that designs and
develops virus-based immunotherapies for the treatment of cancer,
today announces that it will host a virtual Key Opinion Leader
(KOL) event on Wednesday, April 19, 2023 at 12:00 pm ET / 6:00 pm
CET.
The KOL webinar will provide insights on TG4050 from expert
medical oncologist Professor Christian Ottensmeier, MD, PhD, FRCP
(University of Liverpool, La Jolla Institute for Immunology) who
will also discuss the unmet medical need and outlook on treatment
landscape for patients suffering from head and neck cancers. Prof.
Ottensmeier’s presentation will be followed by a Q&A
session.
In addition, Transgene’s management team will provide a company
update, highlighting new Phase I data presented at AACR on April
18, 2023, confirming the high immunogenicity and promising efficacy
profile of TG4050, an individualized neoantigen cancer vaccine
developed by Transgene in collaboration with NEC Corporation.
To register for the event, please click here.
Transgene will also present eight posters and have a booth
(#310) at AACR which is taking place in Orlando, Florida, on April
14-19, 2023.
***
About Transgene Transgene (Euronext: TNG) is a
biotechnology company focused on designing and developing targeted
immunotherapies for the treatment of cancer. Transgene’s programs
utilize viral vector technology with the goal of indirectly or
directly killing cancer cells. The Company’s clinical-stage
programs consist of a portfolio of therapeutic vaccines and
oncolytic viruses: TG4050, the first individualized therapeutic
vaccine based on the myvac® platform, TG4001 for the treatment of
HPV-positive cancers, as well as TG6002, BT-001 and TG6050, three
oncolytic viruses based on the Invir.IO® viral backbone. With
Transgene’s myvac® platform, therapeutic vaccination enters the
field of precision medicine with a novel immunotherapy that is
fully tailored to each individual. The myvac® approach allows the
generation of a virus-based immunotherapy that encodes
patient-specific mutations identified and selected by Artificial
Intelligence capabilities provided by its partner NEC. With its
proprietary platform Invir.IO®, Transgene is building on its viral
vector engineering expertise to design a new generation of
multifunctional oncolytic viruses. Transgene has an ongoing
Invir.IO® collaboration with AstraZeneca. Additional information
about Transgene is available at: www.transgene.fr Follow us on
Twitter: @TransgeneSA
Disclaimer This press release contains forward-looking
statements, which are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
anticipated. The occurrence of any of these risks could have a
significant negative outcome for the Company’s activities,
perspectives, financial situation, results, regulatory authorities’
agreement with development phases, and development. The Company’s
ability to commercialize its products depends on but is not limited
to the following factors: positive pre-clinical data may not be
predictive of human clinical results, the success of clinical
studies, the ability to obtain financing and/or partnerships for
product manufacturing, development and commercialization, and
marketing approval by government regulatory authorities. For a
discussion of risks and uncertainties which could cause the
Company’s actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque”)
section of the Universal Registration Document, available on the
AMF website (http://www.amf-france.org) or on Transgene’s website
(www.transgene.fr). Forward-looking statements speak only as of the
date on which they are made, and Transgene undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230404005860/en/
Transgene: Lucie Larguier Director Corporate
Communications & IR +33 (0)3 88 27 91 04
investorrelations@transgene.fr
Media: MEDiSTRAVA Consulting David Dible / Sylvie
Berrebi / George Underwood +44 (0)203 928 6900
transgene@medistrava.com
Transgene (EU:TNG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Transgene (EU:TNG)
Historical Stock Chart
From Apr 2023 to Apr 2024